<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="Original Research Vaccine-Induced Skewing of T Cell Responses Protects Against" exact="Chikungunya" post="Virus Disease BroeckelRebecca M.1†HaeseNicole1AndoTakeshi1DmitrievIgor2KreklywichCraig N.1PowersJohn1DentonMichael1SmithPatricia1MorrisonThomas E.3HeiseMark45DeFilippisVictor1MessaoudiIlhem6CurielDavid T.2StreblowDaniel N.17*†[], 1Vaccine"/>
 <result pre="is permitted which does not comply with these terms. Abstract" exact="Chikungunya" post="virus (CHIKV) infections can cause severe and debilitating joint"/>
 <result pre="joint and muscular pain that can be long lasting. Current" exact="CHIKV" post="vaccines under development rely on the generation of neutralizing"/>
 <result pre="for protection; however, the role of T cells in controlling" exact="CHIKV" post="infection and disease is still unclear. Using an overlapping"/>
 <result pre="T cell responses to higher levels than normally observed following" exact="CHIKV" post="infection, but the vaccine vectors did not elicit neutralizing"/>
 <result pre="had significantly reduced infectious viral load when challenged by intramuscular" exact="CHIKV" post="injection. Depletion of both CD4+ and CD8+ T cells"/>
 <result pre="cells in vaccinated mice rendered them fully susceptible to intramuscular" exact="CHIKV" post="challenge. Depletion of CD8+ T cells alone reduced vaccine"/>
 <result pre="data demonstrated a protective role for CD8+ T cells in" exact="CHIKV" post="infection. However, CHKVf5-vaccinated mice that were challenged by footpad"/>
 <result pre="vectors expressing only CHIKV-specific CD8+ T cell epitopes followed by" exact="CHIKV" post="challenge in the footpad prevented footpad swelling and reduced"/>
 <result pre="associated with disease, indicating that CHIKV-specific CD8+ T cells prevent" exact="CHIKV" post="disease. These results also indicate that a T cell-biased"/>
 <result pre="that a T cell-biased prophylactic vaccination approach is effective against" exact="CHIKV" post="challenge and reduces CHIKV-induced disease in mice. Chikungunya virus"/>
 <result pre="effective against CHIKV challenge and reduces CHIKV-induced disease in mice." exact="Chikungunya" post="virus (CHIKV) vaccine T cell pathogenesis cytokine Funding Foundation"/>
 <result pre="Institutes of Health10.13039/100000009 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Chikungunya" post="virus (CHIKV) is a mosquito-transmitted virus that causes fever,"/>
 <result pre="reporting limited mobility, depression, and decreased quality of life (4)." exact="CHIKV" post="can rapidly spread and cause disease in millions of"/>
 <result pre="could be involved in viral clearance of persistent joint-localized CHIKV." exact="CHIKV" post="vaccine candidates under development elicit both humoral and cellular"/>
 <result pre="candidates under development elicit both humoral and cellular responses to" exact="CHIKV" post="antigens. CHIKV vaccines currently being pursued in clinical trials"/>
 <result pre="development elicit both humoral and cellular responses to CHIKV antigens." exact="CHIKV" post="vaccines currently being pursued in clinical trials cover a"/>
 <result pre="the direct contribution of vaccine-induced T cells in protection against" exact="CHIKV" post="is rarely characterized. Two preclinical vaccines, the live-attenuated CHIKV/IRES"/>
 <result pre="cells (17–20). Both vaccines elicited humoral and cellular responses against" exact="CHIKV" post="antigens. However, in the context of vaccine-induced neutralizing antibodies,"/>
 <result pre="or CD8+ T cells did not protect A129 mice from" exact="CHIKV" post="(18). However, a modified vaccinia virus ankara (MVA) vaccine"/>
 <result pre="for protection since CD4+ T cell depletion increased susceptibility to" exact="CHIKV" post="challenge (20). While low levels of E2 neutralizing antibodies"/>
 <result pre="been implicated as a major contributor to joint inflammation during" exact="CHIKV" post="infection of mice. Footpad injection of C57BL/6 mice with"/>
 <result pre="CHIKV infection of mice. Footpad injection of C57BL/6 mice with" exact="CHIKV" post="results in edema, arthritis, and tenosynovitis in the ankle"/>
 <result pre="footpad swelling and joint vascular leakage compared to controls after" exact="CHIKV" post="infection, while viral load in the blood remained the"/>
 <result pre="controls (23). Furthermore, therapeutic administration of mice with CTLA4-Ig after" exact="CHIKV" post="infection inhibited T cell recruitment to the ankle and"/>
 <result pre="unclear. Some evidence suggest T cells promote viral clearance during" exact="CHIKV" post="infection. Mice lacking B and T cells (Rag1−/− or"/>
 <result pre="transfer of neutralizing antibodies into Rag1−/− mice fails to clear" exact="CHIKV" post="in tissues of persistently infected animals (9). In addition,"/>
 <result pre="lacking mature B cells (μMT mice) vaccinated with an inactivated" exact="CHIKV" post="vaccine have decreased levels of virus in the serum"/>
 <result pre="of virus in the serum compared to control-vaccinated mice after" exact="CHIKV" post="challenge, although the vaccinated mice also had increased footpad"/>
 <result pre="suggestive of a role of cellular immunity in protection against" exact="CHIKV" post="infection. Antiviral CD8+ T cells have been shown to"/>
 <result pre="the role for antiviral CD4+ and CD8+ T cells during" exact="CHIKV" post="infection. We profiled T cell epitopes recognized in CHIKV"/>
 <result pre="during CHIKV infection. We profiled T cell epitopes recognized in" exact="CHIKV" post="mice using a complete CHIKV (22) overlapping peptide library."/>
 <result pre="T cell epitopes recognized in CHIKV mice using a complete" exact="CHIKV" post="(22) overlapping peptide library. Based upon the results from"/>
 <result pre="Based upon the results from this screen, we generated a" exact="CHIKV" post="fusion gene called CHIKVf5 that encodes several peptides that"/>
 <result pre="study describes a protective role for CD8+ T cells in" exact="CHIKV" post="infection and disease. Materials and Methods Cells Vero cells,"/>
 <result pre="CO2 in DMEM supplemented with 10% FBS and PSG. Viruses" exact="CHIKV" post="SL15649 and CHIKV 181/25 was generated from the infectious"/>
 <result pre="supplemented with 10% FBS and PSG. Viruses CHIKV SL15649 and" exact="CHIKV" post="181/25 was generated from the infectious clones. Briefly, the"/>
 <result pre="RNA was transfected into Vero cells using Lipofectamine 2000 (ThermoFisher)." exact="CHIKV" post="virus stocks were passaged once C6/36 cells for 72"/>
 <result pre="resuspended in PBS and aliquots were stored at −80°C. For" exact="CHIKV" post="limiting dilution plaque assays, 10-fold serial dilutions of virus"/>
 <result pre="thigh (108 PFU, i.m.). Mice were challenged with 103 PFU" exact="CHIKV" post="in a 20 μl volume in the footpad (f.p.),"/>
 <result pre="5% FBS and PSG. Roughly 100 plaque forming units of" exact="CHIKV" post="181/25 were added to serum dilutions, and the complexes"/>
 <result pre="and graphed using GraphPad Prism v6 software. Results Identification of" exact="CHIKV" post="T Cell Epitopes in C57BL/6 Mice Few dominant CHIKV"/>
 <result pre="of CHIKV T Cell Epitopes in C57BL/6 Mice Few dominant" exact="CHIKV" post="T cell epitopes have been experimentally described in C57BL/6"/>
 <result pre="mice (23, 36). To identify T cell epitopes recognized during" exact="CHIKV" post="infection of C57BL/6 mice, we screened T cell responses"/>
 <result pre="we screened T cell responses by IFNγ ELISpot using a" exact="CHIKV" post="18mer peptide library with 10 amino acid overlap. For"/>
 <result pre="splenocytes were isolated and pooled from three mice infected with" exact="CHIKV" post="for 7 or 14 days (Figure 1A) and cultured"/>
 <result pre="wells were scanned and spots were enumerated. We identified several" exact="CHIKV" post="peptides that elicited an IFNγ response that mapped to"/>
 <result pre="responses in C57BL/6 mice at 7 and 14 days post" exact="CHIKV" post="infection. Mice were infected with 1,000 PFU CHIKV SL15649"/>
 <result pre="days post CHIKV infection. Mice were infected with 1,000 PFU" exact="CHIKV" post="SL15649 in the footpad. At 7 or 14 dpi,"/>
 <result pre="14 dpi, mouse splenocytes were isolated and incubated with individual" exact="CHIKV" post="18-mer peptides overlapping by 10 amino acids and 1e5"/>
 <result pre="from three mice were pooled and incubated with each individual" exact="CHIKV" post="18-mer in the CHIKV peptidome. Peptide numbers for reactive"/>
 <result pre="pooled and incubated with each individual CHIKV 18-mer in the" exact="CHIKV" post="peptidome. Peptide numbers for reactive samples are indicated. (B)"/>
 <result pre="immunoreactive peptides in C57BL/6 mice. 18-mer peptide sequence Peptide #" exact="CHIKV" post="protein MSDRKYHCVCPMRSAEDP 10 nsP1 VYAVHAPTSLYHQAIKGV 20 nsP1 HLKGKLSFTCRCDTVVSC 34"/>
 <result pre="E1 KDHIVNYPASHTTLGVQD 458 E1 Splenocytes from C57BL/6 mice infected with" exact="CHIKV" post="were stimulated with CHIKV-specific 18-mer overlapping peptides, and IFNγ"/>
 <result pre="bold lettering. Generation of MCMV and AdV-Vectored Vaccines Directed Against" exact="CHIKV" post="A fusion polypeptide (CHKVf5) was constructed containing two peptides"/>
 <result pre="fusion gene. (A) Shown is the genomic position of the" exact="CHIKV" post="peptides contained in CHIKVf5. (B) The CHIKVf5 fusion gene"/>
 <result pre="3 CHKVf5 vaccines did not protect mice against a footpad" exact="CHIKV" post="challenge. (A) Mice were administered MCMV-CHKVf5, MCMV WT, or"/>
 <result pre="IFNγ ELISpot assays were performed by stimulating the splenocytes with" exact="CHIKV" post="peptides incorporated in the CHKVf5 fusion gene. (C) IFNγ"/>
 <result pre="from mice vaccinated with the indicated vaccine and challenged with" exact="CHIKV" post="SL15649 in the footpad (&quot;#�? indicates too numerous to"/>
 <result pre="by qRT-PCR. The remaining animals were challenged with 1,000 PFU" exact="CHIKV" post="SL15649 s.c. in the right footpad, and four mice"/>
 <result pre="all vaccine groups (Figure 3C). While control mice challenged with" exact="CHIKV" post="developed IFNγ responses to CHIKV peptides, CHKf5-vaccined mice had"/>
 <result pre="While control mice challenged with CHIKV developed IFNγ responses to" exact="CHIKV" post="peptides, CHKf5-vaccined mice had a higher frequency of responding"/>
 <result pre="CHKf5-vaccined mice had a higher frequency of responding cells. After" exact="CHIKV" post="challenge, footpad swelling was monitored from 3 to 16"/>
 <result pre="that T cells do not reduce viral load in the" exact="CHIKV" post="footpad infection model (22, 23). CHKVf5 Vaccines Induced Protective"/>
 <result pre="Protective Responses in Mice Challenged Intramuscularly In general, s.c. footpad" exact="CHIKV" post="infection quickly replicates to high titers in the ankle,"/>
 <result pre="contralateral calf muscle. Figure 4 C57BL/6 mice were infected with" exact="CHIKV" post="by three different routes, and their footpad swelling and"/>
 <result pre="distributions are compared. C57BL/6 mice were infected with 1,000 PFU" exact="CHIKV" post="SL15649 intramuscularly in the right calf (i.m. R calf),"/>
 <result pre="higher levels of IFNγ expressing T cells in response to" exact="CHIKV" post="peptide stimulation compared to the MCMV vaccine platform, T"/>
 <result pre="to CHIKV, but their splenocytes produce IFNγ in response to" exact="CHIKV" post="peptide stimulation. (A) Mice were vaccinated with the indicated"/>
 <result pre="(A) Mice were vaccinated with the indicated vaccine, challenged with" exact="CHIKV" post="i.m., and harvested at 5 dpi. (B) Prior to"/>
 <result pre="CHIKV i.m., and harvested at 5 dpi. (B) Prior to" exact="CHIKV" post="challenge, IFNγ ELISpot assays were performed on vaccinated mice"/>
 <result pre="assay positive controls included convalescent mouse sera from a previously" exact="CHIKV" post="infected mouse (shown in purple) as well as a"/>
 <result pre="T cell depleting antibodies had significantly reduced levels of infectious" exact="CHIKV" post="present in the calf muscle relative to animals that"/>
 <result pre="However, depletion of CD8+ T cells increased levels of infectious" exact="CHIKV" post="present in the calf, which was enhanced in mice"/>
 <result pre="while CD8+ T cells are required for vaccine-mediated protection against" exact="CHIKV" post="i.m. challenge, CD4+ and CD8+ T cells cooperate to"/>
 <result pre="prior to challenge. Mice were infected i.m. with 10,000 PFU" exact="CHIKV" post="SL15649, and (B) ankle and calf tissue viral loads"/>
 <result pre="(D) Splenocytes from vaccinated mice were collected and stimulated with" exact="CHIKV" post="peptides on ELISpot plates. The results of the ELISpot"/>
 <result pre="all groups (Figure 6B). Data in Figure 6C demonstrate that" exact="CHIKV" post="neutralizing antibodies were not present in the vaccinated mice"/>
 <result pre="antibodies were not present in the vaccinated mice prior to" exact="CHIKV" post="challenge. In addition, splenocytes from the various groups were"/>
 <result pre="the muscle tissue. CD8-Specific AdV 260 and AdV 451 Reduce" exact="CHIKV" post="Disease Since CD8+ T cells were essential for the"/>
 <result pre="the CHKVf5 vaccine, we generated adenoviruses individually expressing the CD8-specific" exact="CHIKV" post="peptides 260 and 451. CHIKV-specific T cell responses in"/>
 <result pre="An additional cohort of these vaccinated mice were challenged with" exact="CHIKV" post="i.m. AdV 260 vaccination alone resulted in significantly reduced"/>
 <result pre="with adenovirus-delivered peptides 260 and 451 are protective against i.m." exact="CHIKV" post="challenge. Figure 7 AdV-260 and AdV-451 vaccination elicits T"/>
 <result pre="AdV-451 vaccination elicits T cells responses and protects mice from" exact="CHIKV" post="in ipsilateral calf. (A) Mice were vaccinated with AdV-260"/>
 <result pre="or PBS (i.m.). Mice were infected i.m. with 10,000 PFU" exact="CHIKV" post="SL15649. (B) Prior to CHIKV challenge, IFNγ ELISpot assays"/>
 <result pre="infected i.m. with 10,000 PFU CHIKV SL15649. (B) Prior to" exact="CHIKV" post="challenge, IFNγ ELISpot assays were performed on a subset"/>
 <result pre="protection for the AdV-260 and AdV-451 vaccines using the f.p." exact="CHIKV" post="challenge model as outlined in Figure 8A. Footpad swelling"/>
 <result pre="AdV (Figure 8B), despite having no statistically significant effect on" exact="CHIKV" post="viral RNA loads in the ipsilateral ankles at 8"/>
 <result pre="with AdV-260, AdV-451, or AdV-Control (i.m.) followed by 1,000 PFU" exact="CHIKV" post="challenge in the right footpad. (B) Footpad swelling was"/>
 <result pre="footpad. (B) Footpad swelling was measured for 13 days after" exact="CHIKV" post="footpad challenge. Statistics were performed using Dunnett's multiple comparison"/>
 <result pre="both AdV-260 and AdV-451. Mice were challenged with 1,000 PFU" exact="CHIKV" post="in the footpad. (F) Survival of Ifnar−/− mice vaccinated"/>
 <result pre="with AdV-260 and AdV-451 could improve survival in a lethal" exact="CHIKV" post="mouse model. Mice lacking the type I IFN receptor"/>
 <result pre="the type I IFN receptor (Ifnar1−/−) are extremely susceptible to" exact="CHIKV" post="and succumb to virus infection 3-4 dpi (40), and"/>
 <result pre="cell vaccine could protect immunocompetent mice from footpad swelling after" exact="CHIKV" post="f.p. challenge, and the vaccine provided significant survival advantage"/>
 <result pre="was unknown what role T cells play in protection against" exact="CHIKV" post="infection and disease. In the current study, we mapped"/>
 <result pre="the current study, we mapped the T cell responses to" exact="CHIKV" post="in C57BL/6 mice using an overlapping CHIKV peptide library"/>
 <result pre="cell responses to CHIKV in C57BL/6 mice using an overlapping" exact="CHIKV" post="peptide library in order to identify potential CHIKV targets"/>
 <result pre="an overlapping CHIKV peptide library in order to identify potential" exact="CHIKV" post="targets for development of a T cell vaccine. During"/>
 <result pre="either CD4+ or CD8+ T cells failed to fully restore" exact="CHIKV" post="tissue load to control levels. However, depletion of CD8+"/>
 <result pre="is required for full efficacy but these cells specifically enhance" exact="CHIKV" post="inflammatory joint disease. Second, the CHKVf5 vaccine does not"/>
 <result pre="disease. Second, the CHKVf5 vaccine does not contain any known" exact="CHIKV" post="neutralizing domains. As such, we did not detect neutralizing"/>
 <result pre="domains. As such, we did not detect neutralizing antibodies against" exact="CHIKV" post="in any of the vaccinated mice, and the generation"/>
 <result pre="the vaccinated mice, and the generation of antibody responses against" exact="CHIKV" post="following challenge developed with normal kinetics and amplitude when"/>
 <result pre="vaccine constructs elicit robust T cell responses that protected against" exact="CHIKV" post="in muscle tissues. Finally, we showed that vaccination with"/>
 <result pre="footpad challenge, but it reduced footpad swelling and inflammation following" exact="CHIKV" post="challenge. In addition, the CD8+ T cell vaccine provided"/>
 <result pre="enhanced survival for Ifnar1−/− mice. T cell responses directed against" exact="CHIKV" post="have been reported in humans during both the acute"/>
 <result pre="cells (41). Following the acute phase, patients who recovered from" exact="CHIKV" post="and patients with chronic CHIKV-induced arthritis both had roughly"/>
 <result pre="(42). There is also evidence that T cells can enter" exact="CHIKV" post="infected joint tissues in humans. In a synovial biopsy"/>
 <result pre="infiltrate, but oddly, CD8+ T cells were rarely found (1)." exact="CHIKV" post="RNA and antigen have been detected in joint synovial"/>
 <result pre="Though it is not known whether T cells protect against" exact="CHIKV" post="in humans, our data would suggest that the presence"/>
 <result pre="We showed that vaccinated animals had a significant reduction of" exact="CHIKV" post="titers in the calf muscle. The tissue-specific protection is"/>
 <result pre="directed against different epitopes when compared to those observed following" exact="CHIKV" post="infection. For example, splenocytes from CHIKV infected mice had"/>
 <result pre="to those observed following CHIKV infection. For example, splenocytes from" exact="CHIKV" post="infected mice had high frequencies of IFNγ responses to"/>
 <result pre="in induction of a diverse T cell memory response to" exact="CHIKV" post="epitopes resulting in a more protective phenotype. Neutralizing antibodies"/>
 <result pre="for CHIKV, and it would be essential for a prophylactic" exact="CHIKV" post="vaccine to induce neutralizing antibody responses to protect from"/>
 <result pre="CHIKV vaccine to induce neutralizing antibody responses to protect from" exact="CHIKV" post="acquisition. The data presented here show that a CD8-directed"/>
 <result pre="skew the responses toward additional epitopes for increased protection against" exact="CHIKV" post="acquisition. This approach could be effective for eliminating CHIKV-induced"/>
 <result pre="will examine the effects of therapeutic T cell vaccines against" exact="CHIKV" post="persistence and disease. Data Availability Statement This manuscript contains"/>
 <result pre="1.HoarauJJJaffar BandjeeMCKrejbich TrototPDasTLi-Pat-YuenGDassaBet al.. Persistent chronic inflammation and infection by" exact="Chikungunya" post="arthritogenic alphavirus in spite of a robust host immune"/>
 <result pre="10.4049/jimmunol.090025520404278 2.GérardinPFianuAMalvyDMussardCBoussaïdKRollotOet al.. Perceived morbidity and community burden after a" exact="Chikungunya" post="outbreak: the TELECHIK survey, a population-based cohort study. BMC"/>
 <result pre="population-based cohort study. BMC Med. (2011) 9:5. 10.1186/1741-7015-9-521235760 3.SchilteCStaikowskyFStaikovskyFCoudercTMadecYCarpentierFet al.." exact="Chikungunya" post="virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS"/>
 <result pre="Res. (2015) 120:32–9. 10.1016/j.antiviral.2015.04.01625979669 8.CoudercTKhandoudiNGrandadamMVisseCGangneuxNBagotSet al.. Prophylaxis and therapy for" exact="Chikungunya" post="virus infection. J Infect Dis. (2009) 200:516–23. 10.1086/60038119572805 9.HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSet"/>
 <result pre="200:516–23. 10.1086/60038119572805 9.HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSet al.. Chronic joint disease caused by persistent" exact="Chikungunya" post="virus infection is controlled by the adaptive immune response."/>
 <result pre="dose-escalation trial. Lancet. (2014) 384:2046–52. 10.1016/S0140-6736(14)61185-525132507 13.HallengärdDKakoulidouMLullaAKümmererBMJohanssonDXMutsoMet al.. Novel attenuated" exact="Chikungunya" post="vaccine candidates elicit protective immunity in C57BL/6 mice. J"/>
 <result pre="and active-controlled phase 2 trial. Lancet. (2019) 392:2718–27. 10.1016/S0140-6736(18)32488-730409443 16.RezzaGWeaverSC." exact="Chikungunya" post="as a paradigm for emerging viral diseases: evaluating disease"/>
 <result pre="of adaptive immunity to CHIKV/IRES a novel candidate vaccine against" exact="Chikungunya" post="in the A129 mouse model. Vaccine. (2013) 31:3353–60. 10.1016/j.vaccine.2013.05.05923727003"/>
 <result pre="the A129 mouse model. Vaccine. (2013) 31:3353–60. 10.1016/j.vaccine.2013.05.05923727003 19.RoyCJAdamsAPWangEPlanteKGorchakovRSeymourRLet al.." exact="Chikungunya" post="vaccine candidate is highly attenuated and protects nonhuman primates"/>
 <result pre="Infect Dis. (2014) 209:1891–9. 10.1093/infdis/jiu01424403555 20.Weger-LucarelliJChuHAliotaMTPartidosCDOsorioJE. A novel MVA vectored" exact="Chikungunya" post="virus vaccine elicits protective immunity in mice. PLoS Negl"/>
 <result pre="22.TeoTHLumFMClaserCLullaVLullaAMeritsAet al.. A pathogenic role for CD4+ T cells during" exact="Chikungunya" post="virus infection in mice. J Immunol. (2013) 190:259–69. 10.4049/jimmunol.120217723209328"/>
 <result pre="10.1038/ncomms1352027901019 36.MuthumaniKLankaramanKMLaddyDJSundaramSGChungCWSakoEet al.. Immunogenicity of novel consensus-based DNA vaccines against" exact="Chikungunya" post="virus. Vaccine. (2008) 26:5128–34. 10.1016/j.vaccine.2008.03.06018471943 37.PratheekBMSuryawanshiARChattopadhyayS. In silico analysis"/>
 <result pre="10.1016/j.vaccine.2008.03.06018471943 37.PratheekBMSuryawanshiARChattopadhyayS. In silico analysis of MHC-I restricted epitopes of" exact="Chikungunya" post="virus proteins: implication in understanding anti-CHIKV CD8(+) T cell"/>
 <result pre="T cell response and advancement of epitope based immunotherapy for" exact="CHIKV" post="infection. Infect Genet Evol. (2015) 31:118–26. 10.1016/j.meegid.2015.01.01725643869 38.KarrerUWagnerMSierroSOxeniusAHengelHDumreseTet al.."/>
 <result pre="PLoS Pathog. (2008) 4:e29. 10.1371/journal.ppat.004002918282093 41.WauquierNBecquartPNkogheDPadillaCNdjoyi-MbiguinoALeroyEM. The acute phase of" exact="Chikungunya" post="virus infection in humans is associated with strong innate"/>
 <result pre="of the T cell responses against E2, nsP1 and capsid" exact="CHIKV" post="proteins in recovered and chronic patients after the epidemics"/>
 <result pre="10.1371/journal.pone.008469524376836 43.OzdenSHuerreMRiviereJPCoffeyLLAfonsoPVMoulyVet al.. Human muscle satellite cells as targets of" exact="Chikungunya" post="virus infection. PLoS ONE. (2007) 2:e527. 10.1371/journal.pone.000052717565380 44.TatsisNFitzgeraldJCReyes-SandovalAHarris-McCoyKCHensleySEZhouDet al.."/>
 <result pre="in murine cytomegalovirus infection. J Immunol. (2013) 190:3410–6. 10.4049/jimmunol.120315123455500 Abbreviations" exact="CHIKV" post="Chikungunya virus RRV Ross River virus SINV Sindbis virus"/>
 <result pre="murine cytomegalovirus infection. J Immunol. (2013) 190:3410–6. 10.4049/jimmunol.120315123455500 Abbreviations CHIKV" exact="Chikungunya" post="virus RRV Ross River virus SINV Sindbis virus VEEV"/>
</results>
